The UK and US have hammered out a key bilateral deal that will maintain no duties on UK drug shipments being sold in the US market.
Key Provisions of the Accord
As part of the deal, the UK has agreed to raise expenditure on medicines through the public health system. This move secures that tariffs on these vital goods will be held at nothing for a period of 36 months.
This development comes after earlier threats to dramatically increase duties on branded drug imports, with potential rates mentioned up to one hundred percent.
"This arrangement with the Britain reinforces the global environment for cutting-edge drugs and introduces long-overdue fairness to American-British pharmaceutical trade," a statement declared.
Trade Importance
Pharmaceuticals represent one of the UK's largest export categories to the United States, which is easily the biggest buyer for major British pharmaceutical firms.
Export figures show that in the year leading up to September, the UK exported medicines totaling £11.1bn to the US. This value accounted for a significant portion of total UK exports in that span.
"This guarantee secures work, increases investment and sets the stage for the UK to establish itself as a international leader for biotech and pharma," a government official stated.
Detailed NHS Changes
The agreement entails several specific changes from the British government:
- Revised Affordability Limit: The UK will lift the price threshold at which it judges new therapies to be unaffordable by twenty-five percent.
- Boosted Medicine Funding: There is a goal to double overall public funding on medicines from 0.3% of Gross Domestic Product to 0.6 percent over the following ten-year period.
- Refund Ceiling: The percentage drug companies must return to the NHS to prevent overspending will be capped at fifteen percent. Last year, repayments topped twenty percent.
Recent Tensions
This agreement follows a protracted tension between the sector and the UK government over drug pricing and approval rates.
This friction were exacerbated by arguments that American patients were paying a premium for the same drugs than people in the UK and Europe.
Over the last 18 months, several large drug company projects in the UK have been halted or scrapped, while major funding commitments have been pledged toward projects in the United States.
A senior figure stated that the NHS had to invest a greater share on treatments, noting that its budget allocation on drugs had declined as a proportion of its resources over the previous ten-year period.
